ストックスクリーナーアプリを入手
20.82
7.55%
-1.7032
前日終値:
$22.52
開ける：
$22.01
24時間の取引高:
1.22M
Relative Volume:
0.62
時価総額：
$2.29B
収益：
$12.59M
当期純損益:
$-212.39M
株価収益率:
-6.7471
EPS:
-3.0853
ネットキャッシュフロー:
$-185.92M
1週間 パフォーマンス:
-4.89%
1か月 パフォーマンス:
-13.25%
6か月 パフォーマンス:
+97.91%
1年 パフォーマンス:
+123.63%
1日の値動き範囲:
$20.73
$22.24
1週間の範囲:
$20.73
$22.81
52週間の値動き範囲:
$5.1501
$27.65
Immunome Inc Stock (IMNM) Company Profile
Compare IMNM vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
20.77 | 2.48B | 12.59M | -212.39M | -185.92M | -3.0853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.36 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
724.67 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.19 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.66 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-12 | 開始されました | H.C. Wainwright | Buy |
| 2025-12-01 | 開始されました | Truist | Buy |
| 2025-09-22 | 開始されました | Goldman | Buy |
| 2025-09-05 | 開始されました | Craig Hallum | Buy |
| 2025-04-02 | 開始されました | Lake Street | Buy |
| 2024-11-08 | 開始されました | Stephens | Overweight |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-04-30 | 開始されました | JP Morgan | Overweight |
| 2024-04-15 | 開始されました | Guggenheim | Buy |
| 2024-01-29 | 開始されました | Leerink Partners | Outperform |
| 2023-12-19 | 開始されました | Wedbush | Outperform |
| 2021-10-29 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Immunome Inc (IMNM) 最新ニュース
HC Wainwright Analysts Boost Earnings Estimates for Immunome - MarketBeat
Immunome (IMNM) TTM Net Loss Of US$212 Million Reinforces Bearish Profitability Narratives - simplywall.st
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing - AOL.com
IMNM: Stephens & Co. Lowers Price Target to $30, Maintains Overw - GuruFocus
Immunome (IMNM): Craig-Hallum Raises Price Target to $36.00 and - GuruFocus
Immunome (NASDAQ:IMNM) Price Target Raised to $36.00 - MarketBeat
Stephens Cuts Immunome (NASDAQ:IMNM) Price Target to $30.00 - MarketBeat
Decoding Immunome Inc (IMNM): A Strategic SWOT Insight - GuruFocus
Immunome (IMNM) Reports Wider Losses and Revenue Decline - GuruFocus
Immunome 2025 Net Loss Narrows - marketscreener.com
Immunome (IMNM) Projects Strong Cash Position and Promising Drug Developments - GuruFocus
Earnings Flash (IMNM) Immunome Posts Full Year 2025 Loss $2.43, vs. FactSet Est of $2.24 Loss - marketscreener.com
Immunome: Q4 Earnings Insights - Benzinga
IMNM: Net loss improved to $212.4M in 2025, with $653.5M cash supporting late-stage oncology pipeline - TradingView
Immunome (IMNM) 2025 10-K: Phase 3 varegacestat data and ADC pipeline - Stock Titan
Immunome (IMNM) posts 2025 loss but scores major Phase 3 cancer win - Stock Titan
Immunome Reports Full Year 2025 Financial Results and Provides Business Update - Business Wire
TD Asset Management Inc Purchases 95,750 Shares of Immunome, Inc. $IMNM - MarketBeat
IMNM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
How Immunome’s Oncology Pivot and Varegacestat NDA Push Could Impact Immunome (IMNM) Investors - simplywall.st
Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development - Insider Monkey
11 Best Cancer Stocks to Invest In Now - Insider Monkey
Immunome, Inc. (IMNM) Investor Outlook: Exploring a Promising 60% Upside in the Biotech Sector - DirectorsTalk Interviews
Private Capital Advisors Inc. Has $1.38 Million Stake in Immunome, Inc. $IMNM - MarketBeat
Assessing Immunome (IMNM) Valuation After Recent Share Price Pullback - Yahoo Finance
Immunome to Present at Upcoming March 2026 Investor Conferences - BioSpace
First Week of October 16th Options Trading For Immunome (IMNM) - Nasdaq
Immunome to Present at Upcoming Investor Conferences - The Joplin Globe
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% - Yahoo Finance
Risk Analysis: Is Immunome Inc part of any ETF2025 Year in Review & Technical Pattern Based Signals - baoquankhu1.vn
Immunome, Inc. $IMNM Shares Acquired by NEOS Investment Management LLC - MarketBeat
Immunome, Inc. (IMNM) - DirectorsTalk Interviews
Market Fear: Can Immunome Inc be the next market leaderShort Setup & Weekly Breakout Watchlists - baoquankhu1.vn
Is Immunome, Inc. (IMNM) the best booming stock to buy right now? - MSN
Jim Cramer on Immunome: "If you want to speculate on it, fine" - MSN
Should You Buy Immunome Inc (IMNM) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Redmile Group (IMNM) discloses 5.2% Immunome stake via managed funds - Stock Titan
Brokers Issue Forecasts for Immunome FY2025 Earnings - MarketBeat
Trading Systems Reacting to (IMNM) Volatility - Stock Traders Daily
Immunome CEO Touts Phase 3 Desmoid Win, Near-Term FDA NDA Plan and Early IM-1021 ADC Responses - MarketBeat
Immunome (NASDAQ:IMNM) Stock Rating Upgraded by HC Wainwright - MarketBeat
Institutional investors in Immunome, Inc. (NASDAQ:IMNM) see US$269m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
H.C. Wainwright initiates coverage on Immunome stock with Buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright initiates coverage on Immunome stock with Buy rating - Investing.com Australia
How do insiders feel about Immunome Inc.Market Growth Summary & Daily Stock Trend Reports - mfd.ru
HC Wainwright Initiates Immunome at Buy With $40 Price Target - marketscreener.com
Immunome (IMNM) Initiates Coverage with a Buy Rating by HC Wainw - GuruFocus
This Sezzle Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm
Immunome (IMNM): Biotech minnow in the spotlight as volatility returns to cancer drug hunters - AD HOC NEWS
Principal Financial Group Inc. Buys 762,147 Shares of Immunome, Inc. $IMNM - MarketBeat
Candriam S.C.A. Buys 541,441 Shares of Immunome, Inc. $IMNM - MarketBeat
Immunome Inc (IMNM) 財務データ
収益
当期純利益
現金流量
EPS
Immunome Inc (IMNM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Barchas Isaac | Director |
Dec 22 '25 |
Sale |
21.74 |
383,200 |
8,330,080 |
2,031,181 |
| SIEGALL CLAY B | President and CEO |
Dec 19 '25 |
Buy |
20.48 |
7,278 |
149,053 |
860,525 |
| Tsai Philip | Chief Technical Officer |
Dec 19 '25 |
Buy |
20.49 |
10,000 |
204,900 |
43,300 |
| SIEGALL CLAY B | President and CEO |
Dec 18 '25 |
Buy |
21.50 |
46,511 |
999,986 |
853,247 |
| Higgins Jack | Chief Scientific Officer |
Sep 10 '25 |
Option Exercise |
1.35 |
22,000 |
29,700 |
40,729 |
| BIENAIME JEAN JACQUES | Director |
Jun 03 '25 |
Buy |
9.38 |
5,000 |
46,900 |
36,415 |
| Higgins Jack | Chief Scientific Officer |
Mar 27 '25 |
Option Exercise |
1.35 |
5,200 |
7,020 |
18,729 |
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
4.35%
大文字化:
|
ボリューム (24 時間):